Dr Phillip Fromm

Senior Hospital Scientist/Research Fellow
ANZAC Research Institute, Concord Clinical School

Telephone +61 2 9767 9883/+61 2 9515 8483
Fax +61 2 9767 9883

Website Dendritic Cell Research
ANZAC Research Institute

Map

Biographical details

I combine immunology experience gained in mice during my PhD and now significant human preclinical and clincial immunology following my move to the Dendritic Cell Biology and Therapeutics Group, headed by Professor Derek Hart. I have recognized expertise in the field of flow cytometry and its application to novel scientific questions both in and outside mainstream immunology. I have established strong working collaborations with clinicians and researchers in the Haematology department at the Royal Prince Alfred Hospital (RPAH), that have already led to the publication of high quality research in leading journals (e.g Blood).

My personal vision is to advance the clinical translation of immunotherapy to promote patient outcomes, with a view to modulating immune checkpoints to synergise with other treatment modalities.

I have used my recognized expertise in flow cytometry as a tool to answer fundamental biological questions first in murine models dissecting the role of tumor necrosis factor (TNF) and its receptors in mediating monocyte and dendritic cell development and it impact on mediating immunity to the infectious parasite Leishmania major. This resulted in a major publication that was the first to describe the in vivo consequences of reverse signalling through membrane TNF via TNFR1 to promote monocyte differentiation and innate immunity to L. major infection (P11566704).

My interest in application of flow cytometry to cancer and particularly myeloma is evident by my contributions to both basic and translational science. I have published on the role that chemokine and chemokine receptors have on B cell activation and the affinity maturation of antibody and in dissecting the mechanism of uptake of novel heavy metal Ruthenium complexes as chemotherapeutic agents in malignant B cells.

My translational interests have supported the use of anti-CD83 antibodies as a novel means of immunosuppression in bone marrow transplantation (Leukemia. 2015 Aug 19 ; In press) and reviewed the use of Dendritic cells as modern pharmaceutical tool for cancer treatment (Pharmacol Rev. 2015 Oct;67(4):731-53). He has also supported a recent description of trogocytosis as a novel means of immune evasion in multiple myeloma (Blood 120: 2054), which also led to a commentary in Blood.


I maintain strong ties with clinicians and to the wider audience of haematologists, registrars, nurses, and consumers including patient advovate groups such as the Myeloma Foundation of Australia, the North Shore Prostate Cancer Support Group, the Dendritic Cell Research Consumer committee and the local community through media interviews with local media, (Burwood Scene) on the use of immunotherapy in the treatment of cancer.

Research interests

I have answered fundamental biological questions around the role of tumor necrosis factor (TNF) and its receptors in mediating monocyte and dendritic cell development. This resulted in a major publication that was the first to describe the in vivo consequences of reverse signaling through membrane TNF via TNFR1 to promote monocyte differentiation and innate immunity to L. major infection (J. Immunol 188:6258).

Similarly, I have published on the role that chemokine and chemokine receptors have on B cell activation and the affinity maturation of antibody (Immunol Cell Biol. 91,335) and in dissecting the mechanism of uptake of novel heavy metal Ruthenium complexes as chemotherapeutic agents in malignant B cells (ChemMedChem 6:848,), which is his most highly cited paper and led to an inside cover commentary.

My translational interests have supported the use of anti-CD83 antibodies as a novel means of immunosuppression in bone marrow transplantation (Leukemia. 2015 Aug 19 ; In press) and reviewed the use of Dendritic cells as modern pharmaceutical tool for cancer treatment (Pharmacol Rev. 2015 Oct;67(4):731-53) as well as describing new subsets of human plasmacytoid dendritic cells (Immunol and Cell Biology, 2015, In press) and the differential responses in patients with mutiple myeloma to glucocorticid containing therapeutic regimes Similalry, I have also supported a recent description of trogocytosis as a novel means of immune evasion in multiple myeloma (Blood 120: 2054), which also led to a commentary in Blood.

Most recently,I have engaged with the Human Leukocyte Antigen Differentiation Workshop and was been instrumental in the design, implementation and analysis of submitted antibodies to the international consortium for the current 2014 workshop that resulted in the designation and validation of 7 new clusters of differentiation antigens for both clinical and basic science applications.

Teaching and supervision

I have been involved in the teaching of undergraduate medical and science students in the Faculty of Medicine at James Cook University in the discipline of Biochemistry and Molecular Biology. I have been involved in the supervision of undergraduate students as part of the Summer Research Studentship through the University of Sydney and have currently provided supervision to both honours and postgraduate students. I am keenly interested in the power that single cell analysis using flow cytometry and related techniques can provide to understanding complex biologuical questions in disease.

International links

Australia

(Royal Prince Alfred Hospital) We work closely with academic haematologists and haematology diagnostics departments at RPA, working on projects based around the diagnosis and treatment of haematological malignancies, with a particular emphasis on the role of the immune system and particularly, dendritic as modalities to treat diseases including multiple myeloma, acute myeloid leukemia through the use of immune therapies.

Belgium

(University of Antwerp, Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute (VAXINFECTIO), Laboratory of Experimental Hematology, Antwerp, Belgium,) We collaborate with Prof Zwi Berneman and Dr. Sebastien Anguille on the mRNA laoding of human dendritic cell as theraeputic vaccines for the treatment of haematological malignancies including leukemias, lymphomas and myeloma.

Selected grants

2014

  • EVOS FL Auto cell imaging system; Nicholson G, Clark G, Zhou H, Jessup W, Le Couteur D, McMahon A, McLachlan A, Allan C, Handelsman D, Hart D, Walters K, Kritharides L, Kockx M, Kennerson M, Cooper M, Seibel M, Verma N, Silveira P, Fromm P, Simanainen U, Cogger V, Zheng Y; National Health and Medical Research Council (NHMRC)/Equipment Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Seldon, T., Pryor, R., Palkova, A., Jones, M., Verma, N., Findova, M., Braet, K., Sheng, Y., Fan, Y., Zhou, E., Fromm, P., Silveira, P., Elgundi, Z., Ju, X., Clark, G., Bradstock, K., Hart, D., et al (2016). Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia, 30(3), 692-700. [More Information]
  • Anguille, S., Smits, E., Bryant, C., Van Acker, H., Goossens, H., Lion, E., Fromm, P., Hart, D., Van Tendeloo, V., Berneman, Z. (2015). Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacological Reviews, 67(4), 731-753. [More Information]
  • Favaloro, J., Liyadipitiya, T., Brown, R., Yang, S., Suen, H., Woodland, N., Nassif, N., Hart, D., Fromm, P., Weatherburn, C., Joshua, D., et al (2014). Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leukemia & Lymphoma, 55(12), 2893-2900. [More Information]
  • Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, J., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia & Lymphoma, 55(5), 1090-1098. [More Information]
  • Wiede, F., Fromm, P., Comerford, I., Kara, E., Bannan, J., Schuh, W., Ranasinghe, C., Tarlinton, D., Winkler, T., McColl, S., et al (2013). CCR6 is transiently upregulated on B cells after activation and modulates the germinal center reaction in the mouse. Immunology and Cell Biology, 91(5), 335-339. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]
  • Domingos, J., Fromm, P., Smith-Keune, C., Jerry, D. (2012). A robust flow-cytometric protocol for assessing growth rate of hatchery-reared barramundi Lates calcarifer larvae. Journal of Fish Biology, 80(6), 2253-2266. [More Information]
  • Brown, R., Karieshma, K., Favaloro, J., Yang, S., Joy Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012). CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosis. Blood, 120(10), 2055-2063. [More Information]
  • Anguille, S., Lion, E., Tel, J., de Vries, I., Coudere, K., Fromm, P., Van Tendeloo, V., Smits, E., Berneman, Z. (2012). Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. PloS One, 7(12), 1-13. [More Information]
  • Fromm, P., Gottlieb, D., Bradstock, K., Hart, D. (2011). Cellular therapy to treat haematological and other malignancies: progress and pitfalls. Pathology, 43(6), 605-615. [More Information]
  • Pisani, M., Fromm, P., Mulyana, Y., Clarke, R., Korner, H., Heimann, K., Collins, J., Keene, F. (2011). Mechanism of cytotoxicity and cellular uptake of lipophilic inert dinuclear polypyridylruthenium(II) complexes. ChemMedChem: chemistry enabling drug discovery, 6(5), 848-858. [More Information]
  • Kling, J., Gollan, R., Fromm, P., Koerner, H. (2011). Redundancy of interleukin-6 in the differentiation of T cell and monocyte subsets during cutaneous leishmaniasis. Experimental Parasitology, 129(3), 270-276. [More Information]
  • Körner, H., McMorran, B., Schlüter, D., Fromma, P. (2011). The role of TNF in parasitic diseases: Still more questions than answers. International Journal for Parasitology, 40(8), 879-888. [More Information]
  • Hansen, E., Krautwald, M., Maczurek, A., Stuchbury, G., Fromma, P., Steele, M., Schulz, O., Garcia, O., Castillo, J., Korner, H., et al (2010). A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. Journal of Alzheimer's Disease, 19(2), 451-464. [More Information]
  • Roomberg, A., Kling, J., Fromm, P., Korner, H. (2010). Tumor necrosis factor negative bone marrow-derived dendritic cells exhibit deficient IL-10 expression. Immunology and Cell Biology, 88(8), 842-845. [More Information]
  • Wiede, F., Roomberg, A., Cretney, E., Lechner, A., Fromm, P., Wren, L., Smyth, M., Korner, H. (2009). Age-dependent, polyclonal hyperactivation of T cells is reduced in TNF-negative gld/gld mice. Journal of Leukocyte Biology, 85(1), 108-116. [More Information]

2016

  • Seldon, T., Pryor, R., Palkova, A., Jones, M., Verma, N., Findova, M., Braet, K., Sheng, Y., Fan, Y., Zhou, E., Fromm, P., Silveira, P., Elgundi, Z., Ju, X., Clark, G., Bradstock, K., Hart, D., et al (2016). Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia, 30(3), 692-700. [More Information]

2015

  • Anguille, S., Smits, E., Bryant, C., Van Acker, H., Goossens, H., Lion, E., Fromm, P., Hart, D., Van Tendeloo, V., Berneman, Z. (2015). Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacological Reviews, 67(4), 731-753. [More Information]

2014

  • Favaloro, J., Liyadipitiya, T., Brown, R., Yang, S., Suen, H., Woodland, N., Nassif, N., Hart, D., Fromm, P., Weatherburn, C., Joshua, D., et al (2014). Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leukemia & Lymphoma, 55(12), 2893-2900. [More Information]
  • Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, J., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia & Lymphoma, 55(5), 1090-1098. [More Information]

2013

  • Wiede, F., Fromm, P., Comerford, I., Kara, E., Bannan, J., Schuh, W., Ranasinghe, C., Tarlinton, D., Winkler, T., McColl, S., et al (2013). CCR6 is transiently upregulated on B cells after activation and modulates the germinal center reaction in the mouse. Immunology and Cell Biology, 91(5), 335-339. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]

2012

  • Domingos, J., Fromm, P., Smith-Keune, C., Jerry, D. (2012). A robust flow-cytometric protocol for assessing growth rate of hatchery-reared barramundi Lates calcarifer larvae. Journal of Fish Biology, 80(6), 2253-2266. [More Information]
  • Brown, R., Karieshma, K., Favaloro, J., Yang, S., Joy Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012). CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosis. Blood, 120(10), 2055-2063. [More Information]
  • Anguille, S., Lion, E., Tel, J., de Vries, I., Coudere, K., Fromm, P., Van Tendeloo, V., Smits, E., Berneman, Z. (2012). Interleukin-15-Induced CD56(+) Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. PloS One, 7(12), 1-13. [More Information]

2011

  • Fromm, P., Gottlieb, D., Bradstock, K., Hart, D. (2011). Cellular therapy to treat haematological and other malignancies: progress and pitfalls. Pathology, 43(6), 605-615. [More Information]
  • Pisani, M., Fromm, P., Mulyana, Y., Clarke, R., Korner, H., Heimann, K., Collins, J., Keene, F. (2011). Mechanism of cytotoxicity and cellular uptake of lipophilic inert dinuclear polypyridylruthenium(II) complexes. ChemMedChem: chemistry enabling drug discovery, 6(5), 848-858. [More Information]
  • Kling, J., Gollan, R., Fromm, P., Koerner, H. (2011). Redundancy of interleukin-6 in the differentiation of T cell and monocyte subsets during cutaneous leishmaniasis. Experimental Parasitology, 129(3), 270-276. [More Information]
  • Körner, H., McMorran, B., Schlüter, D., Fromma, P. (2011). The role of TNF in parasitic diseases: Still more questions than answers. International Journal for Parasitology, 40(8), 879-888. [More Information]

2010

  • Hansen, E., Krautwald, M., Maczurek, A., Stuchbury, G., Fromma, P., Steele, M., Schulz, O., Garcia, O., Castillo, J., Korner, H., et al (2010). A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. Journal of Alzheimer's Disease, 19(2), 451-464. [More Information]
  • Roomberg, A., Kling, J., Fromm, P., Korner, H. (2010). Tumor necrosis factor negative bone marrow-derived dendritic cells exhibit deficient IL-10 expression. Immunology and Cell Biology, 88(8), 842-845. [More Information]

2009

  • Wiede, F., Roomberg, A., Cretney, E., Lechner, A., Fromm, P., Wren, L., Smyth, M., Korner, H. (2009). Age-dependent, polyclonal hyperactivation of T cells is reduced in TNF-negative gld/gld mice. Journal of Leukocyte Biology, 85(1), 108-116. [More Information]

To update your profile click here. For support on your academic profile contact .